Literature DB >> 7902335

Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells.

T L Yue1, P J Mckenna, J L Gu, H Y Cheng, R R Ruffolo, G Z Feuerstein.   

Abstract

The protective effects of carvedilol, a new beta-adrenergic receptor blocker and vasodilating antihypertensive agent, against oxygen free radical-mediated injury were studied in cultured bovine endothelial cells and compared with five other beta-blockers. Carvedilol dose-dependently inhibited oxygen radical-induced lipid peroxidation (50% inhibition at 2.6 mumol/L) and glutathione depletion (50% inhibition at 1.8 mumol/L) in the cells. Under the same conditions, other beta-blockers--propranolol, labetalol, pindolol, atenolol, and celiprolol--had only mild or no effect. Moreover, carvedilol protected against oxygen radical--mediated cell damage, as assessed by cellular lactate dehydrogenase release, with a 50% inhibition at 4.1 mumol/L and increased the cell survival in a dose-dependent manner, whereas other beta-blockers had mild or no effects. Pretreatment of the cells with carvedilol for 7 days significantly enhanced the protective effects of carvedilol. Using 2-methyl-2-nitrosopropane as a trapping agent, the spin adduct in cell lipids was monitored by electron paramagnetic resonance. Carvedilol dose-dependently decreased the intensity of the free radical signals, indicating its free radical-scavenging ability. The prevention of oxidative injury to endothelial cells might potentially contribute to the clinical beneficial effects of carvedilol as an antihypertensive agent.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902335     DOI: 10.1161/01.hyp.22.6.922

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

Review 1.  Role of the Maillard reaction in diabetes mellitus and diseases of aging.

Authors:  S R Thorpe; J W Baynes
Journal:  Drugs Aging       Date:  1996-08       Impact factor: 3.923

2.  PF9404C, a new slow NO donor with beta receptor blocking properties.

Authors:  M Villarroya; C J Herrero; A Ruíz-Nuño; R de Pascual; M del Valle; P Michelena; M Grau; E Carrasco; M G López; A G García
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

Review 3.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

4.  The inhibition in tumor necrosis factor-alpha-induced attenuation in endothelial thrombomodulin expression by carvedilol is mediated by nuclear factor-kappaB and reactive oxygen species.

Authors:  Pen-Yuan Lin; Hsi-Che Shen; Chien-Jen Chen; Shu-En Wu; Hsien-Li Kao; Jen-Hung Huang; Danny Ling Wang; Shih-Chung Chen
Journal:  J Thromb Thrombolysis       Date:  2009-03-31       Impact factor: 2.300

Review 5.  Carvedilol: a review of its use in chronic heart failure.

Authors:  Gillian M Keating; Blair Jarvis
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome.

Authors:  Stephan Jacob; Erik J Henriksen
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-12       Impact factor: 3.738

Review 7.  Novel Perspectives in Redox Biology and Pathophysiology of Failing Myocytes: Modulation of the Intramyocardial Redox Milieu for Therapeutic Interventions-A Review Article from the Working Group of Cardiac Cell Biology, Italian Society of Cardiology.

Authors:  Alessia Arcaro; Flora Pirozzi; Annalisa Angelini; Cristina Chimenti; Lia Crotti; Carla Giordano; Daniele Mancardi; Daniele Torella; Carlo G Tocchetti
Journal:  Oxid Med Cell Longev       Date:  2016-01-05       Impact factor: 6.543

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.